Product Information
AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT is a brand product labeled by Mannkind Corporation, priced at $13.0377 per EA under NDC 47918089818. Its NADAC has been published 129 times since Apr 17, 2024.
Manufacturer
Mannkind CorporationNDC
47918089818
Classification
Brand
Dosage Form
KIT
Route
RESPIRATORY (INHALATION)
Effective Date
4/1/2026
Approval Type
Biologic (BLA)
FDA Application
BLA022472On Market Since
12/4/2018
Price Statistics
The NADAC for AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 8.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.0377 per EA |
|---|---|
| All-time high | $13.0377 (Sep 30, 2026) |
| All-time low | $12.0017 (Jun 19, 2024) |
| 52-week high | $13.0377 |
| 52-week low | $12.6097 |
| Median price | $12.6097 |
| Average price | $12.5401 |
| Largest weekly change | +5.0% (Dec 18, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 40% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mannkind Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
INSULIN HUMAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT?
The current National Average Drug Acquisition Cost (NADAC) for AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT, manufactured by Mannkind Corporation, is $13.0377 per EA (NDC 47918089818), effective Sep 30, 2026.
How has the price of AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT changed over time?
Over the history we have for it, the NADAC for AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT has risen 8.4%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT?
Since Apr 17, 2024, the NADAC for AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT has ranged from a low of $12.0017 (Jun 19, 2024) to a high of $13.0377 (Sep 30, 2026), with a median of $12.6097 per EA.
Are there cheaper alternatives to AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT, is $7.7805 per EA — about 40% below AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT.
Who manufactures AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT?
AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT (NDC 47918089818) is labeled by Mannkind Corporation, and CMS classifies it as a brand product.